<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01164488</url>
  </required_header>
  <id_info>
    <org_study_id>NP25293</org_study_id>
    <nct_id>NCT01164488</nct_id>
  </id_info>
  <brief_title>A Study of RO5190591 (Danoprevir) in Healthy Volunteers</brief_title>
  <official_title>A Two-Way Interaction Study Between RO5190591/RTV and Ketoconazole in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This non-randomized, open-label study will evaluate the interaction of
      RO5190591(danoprevir)/ritonavir with and without ketoconazole and the safety and tolerability
      in healthy volunteers. Participants will be administered repeated daily doses of ketoconazole
      alone, RO5190591/ritonavir, and RO5190591/ritonavir plus ketoconazole. The anticipated time
      on study treatment is 25 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the interaction between RO5190591/ritonavir and ketoconazole</measure>
    <time_frame>Day 40</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of multiple doses of RO5190591/ritonavir without and with ketoconazole</measure>
    <time_frame>Day 40</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danoprevir</intervention_name>
    <description>Repeated daily doses</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoconazole</intervention_name>
    <description>Repeated daily doses</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>Repeated daily doses</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult healthy volunteers, aged 18-64 years, inclusively

          -  Weight &gt;/=50.0 kg

          -  Body Mass Index (BMI) 18.0-32.0 kg/m2

          -  Ability and willingness to abstain from alcohol, xanthine-containing beverages or food
             (coffee, tea, cola, chocolate, &quot;energy drinks&quot;) from 48 hours prior to entry in the
             clinical study center until discharge

          -  Ability and willingness to abstain from grapefruit or grapefruit juice, star fruit,
             and Seville oranges from 7 days prior to entry in the clinical study center until
             discharge

          -  Medical history without major recent or ongoing pathology

        Exclusion Criteria:

          -  Pregnant or lactating women and male partners of women who are pregnant or lactating

          -  Sustained supine systolic blood pressure &gt;140 or &lt;90 mmHG and supine diastolic blood
             pressure &gt;90 or &lt;50 mmHG at Screening or Day -1

          -  Resting heart rate &gt;100 or &lt;45 beats per minute at Screening or Day -1

          -  Any history of clinically significant cardiovascular or cerebrovascular disease

          -  Positive drug test result at screening or each admission

          -  Donation or loss of blood over 450 ml (1 pint) within 60 days prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

